BVD2-23B6 represents a innovative therapeutic approach intended to directly block individual granulocyte-macrophage colony-stimulating factor. Developed via cutting-edge molecule creation methods, this agent https://www.targetmol.com/compound/anti-human-gm-csf-antibody-bvd2-23b6